With several successful procedures already accomplished, Arizona Breastnet in Scottsdale is helping to bring a groundbreaking new procedure to treat breast cancer without the trauma of surgery into the mainstream.
Cryoablation utilizing the innovative IceSense3 System is the application of extreme cold to certain types of breast tumors to treat them without tissue removal, extensive time on the operating table and minimal scarring. Potentially, it will usher in a new paradigm in the treatment of the disease, according to a press release.
According to Belinda Barclay-White, MD, who performs the procedure, it involves placing a small IceSense3 nitrogen-cooled probe into the center of a tumor to freeze it from the inside out. The rapid temperature drop causes diseased cells to crack open and die. The dead cells are then absorbed by the immune system over time.
The benefits of cryoablation over traditional surgical tumor removal are significant, including fast recovery, improved cosmetic results, greater patient comfort, no need for general anesthesia or a hospital operating room and lower cost, the release stated.
Cryoablation essentially involves a nick in the skin and the destruction of a tumor in place with minimal discomfort. The procedure is typically performed in a physician’s office under ultrasound guidance in less than 30 minutes.
Cryoablation is well-established for the treatment of liver, kidney, prostate and other cancers. Recent studies, including the recent ACOSOG Z1072 trial and extensive long-term ongoing studies in Japan, have suggested the effectiveness of cryoablation for certain breast malignancies. The IceSense3 Cryoablation System, developed by IceCure Medical specifically for breast applications, has a long history of successful treatment of benign breast fibroadenomas and is being studied in various other malignant diseases including lung and kidney.
“We are extremely pleased to give selected women an opportunity to take advantage of the clinical and quality-of-life benefits of this treatment and to see its full promise move rapidly towards fruition,” stated Dr. Barclay-White in the release.
The ongoing refinement of cryoablation technology itself makes treatment more effective. The IceSense3 device delivers a stable cycle of extremely cold temperatures and relies on a maneuverable, disposable probe and compact high tech console. For the first time, these advances make precise targeting of tumors extremely reliable, according to the press release.
The effectiveness of cryoablation is being proven in the ongoing prospective, national multi-center ICE3 trial with about 100 patients already treated.
Arizona Breastnet is participating in a concurrent cryoablation registry program that enables a greater number of patients to benefit from the treatment than typical of a clinical trial while the results are still tracked. As a market leader in cryoablation treatment of breast disease, IceCure will utilize its resources to provide clinical and technological support to registry and cancer trial sites.
The Scottsdale Independent is available for free every Wednesday.